Phaseline

Targets › PARG

PARG (Poly(ADP-ribose) glycohydrolase): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Dec 2026.

Poly(ADP-ribose) glycohydrolase that degrades poly(ADP-ribose) by hydrolyzing the ribose-ribose bonds present in poly(ADP-ribose). Mainly acts as an exo-glycohydrolase but can act as an endo-glycohydrolase at low efficiency, releasing poly(ADP-ribose) of different length as well as ADP-ribose monomers. (UniProt, Q86W56)

Open in Phaseline: the race on PARG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
858 TherapeuticsETX-19477
PARG inhibitor
PARGPhase 1Advanced or Metastatic Solid TumorsDec 2026
Evopoint BiosciencesXNW29016
PARG inhibitor
PARGPhase 1Tumor, SolidFeb 2027
IDEAYA BiosciencesIDE-161
PARG inhibitor
PARGPhase 1Advanced or Metastatic Solid TumorsMay 2027
FoRx TherapeuticsFORX-428
PARG inhibitor
PARGPhase 1Advanced Solid TumorsJun 2027

Conditions

Advanced or Metastatic Solid Tumors (2) Advanced Solid Tumors (1) Tumor, Solid (1)

Modalities

small molecule (3), mixed (1)

Companies

FoRx Therapeutics (1) Evopoint Biosciences (1) 858 Therapeutics (1) IDEAYA Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.